Abstract 171P
Background
To evaluate the prognostic value of prognostic nutritional index(PNI)in esophageal cancer patients under minimally invasive esophagectomy (MIE) with peritoneal metastasis.
Methods
The clinical and pathological data of 197 patients under MIE with anastomotic leakage from January 2013 to December 2015 were analyzed retrospectively.
Results
PNI was not associated with various clinicopathological factors such as age, gender, smoking history, tumor location, tumor length, differentiation degree, T stage, N stage, treatment mode, TNM stage and lymph node metastasis rate (P > 0.05). Univariate survival analysis showed that male, smoking history, advanced tumor stage, tumor length>5cm, advanced N stage, higher lymph node metastasis rate, advanced TNM stage, and treatment modality were associated with poor prognosis. Multivariate analysis showed that N stage (HR = 6.108, CI:1.614-23.113, P = 0.008) and treatment modality (HR = 0.362, CI: 0.213-0.617, P < 0.001) are independent risk factors. PNI is not an independent risk factor.
Conclusions
Prognostic nutritional index is not an independent risk factor of the prognosis for patients under minimally invasive esophagectomy with anastomotic leakage. Treatment method and lymph node metastasis are still the main factors affecting long-term survival in this group.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The 4th Hospital of Hebei Medical University.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
196P - The tolerability and efficacy of FOLFIRINOX in gastro-oesophageal carcinoma
Presenter: Nicholas Travers
Session: Poster display session
Resources:
Abstract
197TiP - GLOW: Zolbetuximab + CAPOX compared with placebo + CAPOX as first-line treatment for patients with Claudin18.2+/HER2– Locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized phase III study
Presenter: Rui-Hua Xu
Session: Poster display session
Resources:
Abstract
198TiP - SPOTLIGHT: Comparison of zolbetuximab or placebo + mFOLFOX6 as first-line treatment in patients with claudin18.2+/HER2– locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (GEJ): A randomized phase III study
Presenter: Kensei Yamaguchi
Session: Poster display session
Resources:
Abstract
199TiP - Phase III (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) vs sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy
Presenter: Thomas Yau
Session: Poster display session
Resources:
Abstract
200P - Apalutamide (APA) plus androgen deprivation therapy (ADT) for metastatic castration-sensitive prostate cancer (mCSPC): Analysis of pain and fatigue in the TITAN study
Presenter: Byung Ha Chung
Session: Poster display session
Resources:
Abstract
201P - Efficacy and safety of darolutamide in non-metastatic castration-resistant prostate cancer (nmCRPC) in the ARAMIS trial
Presenter: Jacob See-tong Pang
Session: Poster display session
Resources:
Abstract
202P - What is the best first-line therapy for metastatic castration-sensitive prostate cancer in 2019? A network meta-analysis
Presenter: Tsz Him So
Session: Poster display session
Resources:
Abstract
203P - Long term outcomes of 2-weekly docetaxel in metastatic high-volume hormone sensitive prostate cancer
Presenter: Suhas Singla
Session: Poster display session
Resources:
Abstract
204P - The effect of radium-223 therapy in agent orange related veterans with metastatic castrate resistance prostate carcinoma (CRPC)
Presenter: Andrew Liman
Session: Poster display session
Resources:
Abstract
205P - Treatment pattern and outcomes of radium-223 (Ra223) in metastatic castration resistant prostate cancer (mCRPC): Retrospective cohort analysis from Hong Kong
Presenter: Darren Poon
Session: Poster display session
Resources:
Abstract